Merck & Co., Inc. is 22.5x more valuable than BridgeBio Pharma, Inc. by market capitalization ($294.13 B vs $13.09 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BBIO | MRK |
|---|---|---|
| Market cap | $13.09 B | $294.13 B |
| US-listed rank | #793 | #44 |
| Revenue (latest FY) | $502.08M | $65.01B |
| Net income (latest FY) | - | $18.25B |
| Net margin | - | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 777 | 996 |
Merck & Co., Inc. is 22.5x more valuable than BridgeBio Pharma, Inc. by market capitalization ($294.13 B vs $13.09 B).
In their latest fiscal years, BridgeBio Pharma, Inc. reported $502.08M in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: BridgeBio Pharma, Inc. and Merck & Co., Inc., or browse the full rankings.